Also known as BPC-157/TB-500 · BPC157 TB500 · BPC-157 TB-500 blend
The two most-studied repair peptides pre-mixed — BPC-157 for angiogenesis and tendon/gut healing, TB-500 for actin-driven cell migration.
Research refreshed
A combination of the gastric pentadecapeptide BPC-157 and TB-500 (the synthetic fragment of Thymosin β4). The two are paired on the rationale that they act on different limbs of tissue repair — BPC-157 on angiogenesis, growth-factor expression, and the nitric-oxide system; TB-500 on actin regulation and cell migration — so a blend is proposed to cover more of the healing cascade than either alone. It is a research combination: the peptides are studied individually in preclinical work, and no controlled study has tested the mixture or any fixed ratio in humans.
BPC-157 and TB-500 are the two peptides most often combined in the recovery literature because their proposed mechanisms sit at different points of the repair cascade. BPC-157 is studied for angiogenesis, tendon-to-bone healing, and gut-lining protection; TB-500 for the actin dynamics that drive cell migration into a wound. The pairing is a hypothesis that covering both ends of the process does more than either peptide alone.
That hypothesis has not been tested as a blend. The human evidence for each component is itself limited and largely preclinical, and combining two research peptides does not combine their evidence — it compounds the unknowns around purity, stability in a shared vial, and interaction. This is a research reference, not a protocol; neither component is FDA-approved.
BPC-157: angiogenesis, VEGFR2/eNOS signaling, growth-factor upregulation. TB-500: G-actin sequestration promoting cell migration and wound closure. Mechanisms are complementary, not additive by any measured synergy.
Behind every vial of BPC-157 + TB-500 is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how BPC-157 + TB-500, specifically, is brought into being.
BPC-157 + TB-500 begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
BPC-157 + TB-500 is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — BPC-157 + TB-500 plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of BPC-157 + TB-500 proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of BPC-157 + TB-500 — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
This is a physical mixture, not a single molecule. BPC-157 and TB-500 are each synthesized and purified separately, so there is no combined synthesis and no single purity number — a meaningful certificate shows a separate identity and purity assay for each peptide plus the amount of each in the vial. Two peptides sharing one lyophilized cake and one solution also raise stability and compatibility questions a single-peptide product does not.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
A pre-mixed combination of two repair peptides — BPC-157 and TB-500 — paired for their complementary roles in angiogenesis and cell migration. It is a research combination, not an approved therapy.
No. Each peptide is studied separately, mostly in preclinical models. No controlled study has tested the mixture or a fixed ratio, so combined effects are unestablished.
Their proposed mechanisms sit at different points of the healing cascade — BPC-157 on angiogenesis and growth factors, TB-500 on actin-driven cell migration — so the pairing aims to cover more of the process.
No — neither component is FDA-approved. This page is a research and educational reference, not medical advice.
BPC-157 + TB-500 is a blend. Each component is a single compound with its own catalog monograph — purity, mechanism, and research are documented per component below.
A 43-residue actin buffer. It holds G-actin so cells can move, and its first four residues become the anti-fibrotic peptide Ac-SDKP.
ViewA 27-residue single-chain relaxin-2 analog and selective RXFP1 agonist — a simplified relaxin mimetic studied for anti-fibrotic effects.
ViewEndogenous copper-binding tripeptide widely studied in skin and hair biology.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.